🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Atara Biotherapeutics, Inc. ATRA PHARMA

Healthcare · Biotechnology · United States
https://www.atarabio.com
Company Profile ↓
$10.23
-15.66% 1Y
Mkt Cap$102.69M
P/E-6.64
P/B-2.53
52W High$18.09
52W Low$4.18
Book Value$-3.92
EPS (TTM)$-1.54

Company Overview

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 23.8% CAGR over the past five years.

Recent Developments

  • Dec 2025 Revenue of $120.77M (-6.3% YoY); net profit $32.69M.
  • Trailing 12 Months Year-on-year growth — revenue -96.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 23.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:23.85%
1 Year:-96.40%

Stock Price Performance

1 Year:-15.66%
6 Months:+53.14%
3 Months:+6.78%
1 Month:+21.07%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 43% of range
$4.18 $18.09
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)62.96 · Neutral
Price Performance
1M+21.07%
3M+6.78%
6M+53.14%
1Y-15.66%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 23.8% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading 43.5% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-6.64
Industry PE
24.83
Forward P/E
6.62
PEG Ratio
-
Book Value
$-3.92
Price to Book
-2.53
P/S
16.06
EV/EBITDA
-9.29
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
23.85%
Profit 5Y
-
Revenue (YoY)
-96.40%
Earnings (YoY)
-

Profitability & Returns

ROCE
-
ROE
-84.90%
ROA
-24.14%
Profit Margin
-
Op Margin
-
Gross Margin
75.27%
EPS (Latest Qtr)
$-0.29
EPS (TTM)
$-1.54

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
1.49
Current Ratio
1.98
Debt
$9.88M
Total Assets
$20.00M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
16.80%
Chg in Prom Hold
1.66%
FII / Inst Holding
57.67%
Chg in FII Hold
5.17%

Financial Snapshot

Enterprise Value
$102.69M
Total Revenue (TTM)
$6.19M
EBITDA
$-11.06M
Free Cash Flow
$-12.52M
Operating Cash Flow
$-21.89M
Shares Outstanding
10.04M
Gross Margin
75.27%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ATRA Atara Biotherapeutics, Inc. PHARMA 10.23 -6.64 $102.69M 0.00% - -84.90% 23.85% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue -------------------------------27.36M28.64M40.19M98.15M17.57M3.45M516.00K
Operating Income -2.55M-7.08M-4.53M-5.95M-9.31M-15.11M-12.26M-17.06M-19.48M-25.94M-26.16M-27.91M-31.66M-42.45M-52.62M-60.22M-67.89M-75.53M-72.56M-74.70M-77.95M-74.71M-78.25M-84.00M-84.81M-88.22M-32.13M-84.62M-75.02M-71.41M-69.61M-31.25M-18.23M-21.76M38.80M3.20M-3.57M-3.37M
Net Income -2.54M-7.05M-4.51M-5.92M-9.16M-14.95M-11.87M-16.56M-18.88M-25.37M-25.65M-27.43M-31.10M-41.44M-50.88M-58.36M-66.26M-74.33M-71.89M-73.51M-77.46M-74.35M-78.33M-83.79M-84.66M-88.11M18.47M-84.09M-74.77M-71.11M-69.80M-31.75M-19.05M-21.91M38.01M2.39M-4.30M-4.14M
Diluted EPS ------------------------0.91-0.90-0.870.18-0.82-0.72-16.91-16.40-5.65-3.10-2.933.500.19-0.32-0.29
R&D Expense ----5.77M11.51M8.11M11.25M12.99M18.80M17.54M18.30M20.60M28.46M33.39M43.35M48.67M52.25M53.54M57.66M61.56M59.88M64.06M68.47M70.33M74.96M64.90M70.16M62.16M56.14M56.89M45.51M33.33M43.92M27.43M7.31M2.92M164.00K

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue ---------63.57M8.57M128.94M120.77M
Operating Income -8.62M-28.16M-58.45M-81.24M-121.53M-237.11M-295.68M-309.05M-340.46M-280.51M-276.01M-83.44M35.86M
Net Income -8.77M-28.01M-57.22M-79.05M-119.49M-230.70M-290.98M-306.62M-340.14M-228.30M-276.13M-85.40M32.69M
Diluted EPS --------4.15-3.63-2.24-65.19-11.412.57
R&D Expense -15.45M41.62M56.51M81.21M167.46M216.10M244.65M282.00M272.53M224.78M151.48M37.45M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -51.83M106.12M324.98M263.91M217.78M391.84M342.94M588.12M468.13M376.42M165.50M109.10M20.23M
Total Equity -3.73M-11.02M103.18M315.10M253.74M177.86M339.22M290.78M462.34M279.61M126.64M99.23M-97.28M-38.50M
Cash & Equivalents 4.21M51.62M21.90M23.75M47.97M79.22M60.70M74.32M200.40M106.08M92.94M25.84M25.03M8.48M
Total Liabilities -1.75M2.94M9.88M10.18M39.91M52.98M52.16M125.78M188.51M249.78M264.74M206.38M58.74M
Current Liabilities -1.52M2.72M9.71M9.68M27.65M39.98M36.74M82.90M105.79M78.92M142.23M134.57M14.92M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ----60.02M-87.50M-179.77M-235.63M-180.76M-220.52M-270.43M-192.98M-68.72M-50.94M
Investing Cash Flow ---83.74M99.91M-196.29M60.46M-120.73M22.26M202.96M123.87M8.62M18.15M
Financing Cash Flow ---506.00K20.05M357.54M188.79M427.57M103.94M53.08M2.01M59.28M16.10M
Capital Expenditure -3.00K-46.00K-290.00K-3.02M-20.23M-35.92M-5.73M-4.51M-10.58M-4.19M-1.22M-246.00K-0
Free Cash Flow ----63.05M-107.73M-215.70M-241.36M-185.27M-231.10M-274.62M-194.20M-68.96M-50.94M

Ratios (Annual)

Figures in %.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------
Operating Margin % ----------441.2%-3,219.5%-64.7%29.7%
Net Margin % ----------359.1%-3,220.9%-66.2%27.1%
ROE % 79.6%-27.1%-18.2%-31.2%-67.2%-68.0%-100.1%-66.3%-121.6%-180.3%-278.3%87.8%-84.9%
ROCE % -17.1%-27.2%-18.5%-32.0%-63.9%-67.4%-96.6%-61.2%-94.0%-94.3%-1,185.7%327.5%675.0%

Shareholding Pattern

Insiders
16.80%
Institutions
57.67%
Public Float
69.31%

Top Institutional Holders

#Holder% HeldSharesValue
1 EcoR1 Capital, LLC 15.46% 1.55M $15.04M
2 Adage Capital Partners GP L.L.C. 8.47% 850.00K $8.24M
3 Point72 Asset Management, L.P. 6.85% 687.72K $6.66M
4 Redmile Group, LLC 4.40% 441.70K $4.28M
5 Vanguard Capital Management LLC 2.46% 247.05K $2.39M
6 Mackenzie Financial Corporation 2.32% 233.25K $2.26M
7 Blackrock Inc. 0.84% 84.45K $818.37K
8 Geode Capital Management, LLC 0.75% 75.13K $727.99K
9 Staley Capital Advisers, Inc. 0.50% 50.00K $484.50K
10 Vanguard Fiduciary Trust Co 0.43% 43.04K $417.02K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ATRA

Google News ue, 08 Sep 2026

Insider Purchase: Director at $ATRA Buys 104,166 Shares - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOdkpKMFdFSTNZVkNqdk5nUThRMW1BZTFWWHNBb2xJaV80M2h0SEg3cDdRZURWWUdFOERyN00ybmdUMndrMlRnVkVKWXZZTER6aXlISlR1MXVxZlV6ZHhubXdqanJsbjV1azRSYUdOV25pbHZWUXliSnBaR1c3T1psRTlhRjlHb0RzMVNMTm…

Google News Sun, 06 Sep 2026

Independent Director of Atara Biotherapeutics Picks Up 272% More Stock - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxPMEdvWXNlcHpYRTluTGpkNTJUeV90WDkxZFFVWWRJc20tampoZ3p0S2hiOTdlOTdnYTcwUktXWHJadmZlOVJXR0NzYmEtREtjN3hMeXE4V29sU0p2MDhoZGhVaEY3TzMzRHNteGNpdl9KYzQ2dklVLUZkaW1MZkgtaFVKMURyeExVUjMyVn…

Google News hu, 21 May 2026

ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQcHdldy1kSHNZQ0NtTmVwRjJ6TzlBeVA5Um5CSk5FX2hEWjBBYzFOcFNiWldmTE85ZTUyYlNxSzNFWFBkSkVhZV9kWGlIWUhrOGVFMlc1WEVGcjZaM0JmYmpiUkxJOWZPVzN1S3ZQalo4a1JhUFF5aEtySWpHTXZOT3JiN01XSS1qa3JONV…

Google News Fri, 04 Sep 2026

(ATRA) Movement as an Input in Quant Signal Sets - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQT3d1aVdlcHFYSWh2MF84LUVQMXFuZmRwTU8yRHpKTWNUaDFNWEZURnE2bjZjWVp2dFFpMThaUXltd1p5cUQtN1VIUVhLSFNNQTYtZVF3RVhVR2tnWGhFTHpEUGVvUlhGY3psTG9rZHVycWdPZWVEbGVvQS16ZUVSLWxYLW9VWGNsbndvUD…

Google News Fri, 04 Sep 2026

Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares - Investing.com

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNV2U4YzhialBwRzBMV25JM014UDBGTXd6bzFIczVPSzZ3dTNVSGkxOWR0ZUlEWTdNNXhRM3c0NWVwY2tPdVkxcnFBVUtITUhWOW1mVnFJOWZVb1IzRW9FZVY5d3VZT3BSd2wzczJPZjZRUXZBbFBDR1R0QU9mVTFaYTUtNHMweEFXenRLWV…

Google News hu, 25 Jun 2026

ATRA Forecast — Price Target — Prediction for 2027 - tradingview.com

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1VdkxRUWpRTUl6VG45dlVMaXVRM1Z0SV82NXVhMF91Nk4tVXVIMGdzenhtYk9QeF9xZGVycFcxOE9pSU41YXQ1SWtLSWFoRGxKZFlqaTFKNk15MUhKOFAxVE0wWlNQd2Vlb1RjLTViUDN4dExmM0ZPbmp3?oc=5" target="_blank">ATR…

ATRA — Frequently Asked Questions

What is the current share price of Atara Biotherapeutics, Inc. (ATRA)?

As of 2026-09-19 21:16 PDT, Atara Biotherapeutics, Inc. (ATRA) trades at $10.23 on NasdaqGS. Its 52-week range is $4.18 to $18.09.

What is the market capitalisation of ATRA?

Atara Biotherapeutics, Inc. (ATRA) has a market capitalisation of $102.69M on NasdaqGS.

What is the P/E ratio of ATRA?

ATRA trades at a trailing price-to-earnings (P/E) ratio of -6.64. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -2.53.

What is the return on equity (ROE) of ATRA?

ATRA has a return on equity (ROE) of -84.90%.

Is ATRA a good stock to buy?

This page provides a data-driven analysis of Atara Biotherapeutics, Inc. (ATRA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space